Hematology & Oncology

Medicine & Life Sciences

1. Neoplasms 100%
2. Renal Cell Carcinoma 70%
3. Therapeutics 46%
4. Non-Small Cell Lung Carcinoma 45%
5. Diphtheria Toxin 41%
6. Survival 37%
7. Immunotoxins 35%
8. palmitoyl-protein thioesterase 33%
9. Mutation 32%
10. Acute Myeloid Leukemia 32%
11. Proteins 32%
12. Lung Neoplasms 31%
13. Drug Therapy 30%
14. Ricin 28%
15. Glioblastoma 26%
16. Nivolumab 26%
17. Breast Neoplasms 26%
18. Genes 23%
19. Brain Neoplasms 21%
20. Immunotherapy 20%
21. Safety 20%
22. Neoplasm Metastasis 19%
23. Melanoma 19%
24. Radiotherapy 18%
25. Clinical Trials 18%
26. Leukemia 18%
27. Ceroid lipofuscinosis, neuronal 1, infantile 18%
28. Progression-Free Survival 18%
29. anthrax toxin 18%
30. Pharmaceutical Preparations 17%
31. Bone Marrow 17%
32. Cell Line 17%
33. Prostatic Neoplasms 16%
34. Growth 16%
35. Huntingtin Protein 16%
36. Neuronal Ceroid-Lipofuscinoses 15%
37. Granulocyte-Macrophage Colony-Stimulating Factor 15%
38. Enzymes 15%
39. Glioma 15%
40. Sunitinib 14%
41. ErbB Receptors 14%
42. Stem Cells 14%
43. T-Lymphocytes 14%
44. Brain 14%
45. Colorectal Neoplasms 13%
46. Monoclonal Antibodies 13%
47. Ipilimumab 12%
48. Graft vs Host Disease 12%
49. In Vitro Techniques 12%
50. Liver 12%
51. Recurrence 12%
52. Antibodies 12%
53. Transplants 12%
54. Blood Platelets 12%
55. Thrombosis 12%
56. Interleukin-3 12%
57. alpha-hydroxyglutarate 11%
58. Protein-Tyrosine Kinases 11%
59. Heterografts 11%
60. Sickle Cell Anemia 11%
61. Adenocarcinoma 11%
62. DNA 11%
63. Vascular Endothelial Growth Factor A 11%
64. Isocitrate Dehydrogenase 11%
65. Tissue Donors 11%
66. Apoptosis 10%
67. Pharmacokinetics 10%
68. Vitamin B 12 10%
69. Blood-Brain Barrier 10%
70. Bone Marrow Transplantation 10%
71. Kidney Neoplasms 10%
72. Interleukin-3 Receptors 10%
73. Population 10%
74. Multiple Myeloma 10%
75. Confidence Intervals 10%
76. Bevacizumab 10%
77. Fluorouracil 10%
78. Kidney 9%
79. Barrett Esophagus 9%
80. Interleukin-2 9%
81. Lung 9%
82. Cisplatin 9%
83. Lymphoma 9%
84. Carcinogenesis 9%
85. Peptides 9%
86. Everolimus 9%
87. Small Cell Lung Carcinoma 9%
88. Thrombocytopenia 9%
89. Hematologic Neoplasms 9%
90. Maximum Tolerated Dose 8%
91. Biomarkers 8%
92. Pancreatic Neoplasms 8%
93. Docetaxel 8%
94. Erlotinib Hydrochloride 8%
95. Precursor Cell Lymphoblastic Leukemia-Lymphoma 8%
96. Serum 8%
97. Mechanistic Target of Rapamycin Complex 1 8%
98. Epithelial Cells 8%
99. bavituximab 8%
100. Ligands 8%